SOLIFENACIN TRIMA 5

देश: इसराइल

भाषा: अंग्रेज़ी

स्रोत: Ministry of Health

सक्रिय संघटक:

SOLIFENACIN SUCCINATE

थमां उपलब्ध:

TRIMA ISRAEL PHARMACEUTICAL PRODUCTS MAABAROT LTD

ए.टी.सी कोड:

G04BD08

फार्मास्यूटिकल फॉर्म:

TABLETS

रचना:

SOLIFENACIN SUCCINATE 5 MG

प्रशासन का मार्ग:

PER OS

प्रिस्क्रिप्शन प्रकार:

Required

द्वारा बनाया गया:

TRIMA ISRAEL PHARMACEUTICAL PRODUCTS MAABAROT LTD, ISRAEL

चिकित्सीय क्षेत्र:

SOLIFENACIN

चिकित्सीय संकेत:

For symptomatic treatment of urge incontinence and/or increased urinary frequency and urgency as may occur in patients with overactive bladder syndrome

प्राधिकरण की तारीख:

2019-06-30

सूचना पत्रक

PATIENT LEAFLET IN ACCORDANCE WITH THE
PHARMACISTS’ REGULATIONS (PREPARATIONS) – 1986
The medicine is dispensed with a doctor’s prescription only
SOLIFENACIN-TRIMA 5
SOLIFENACIN-TRIMA 10
FILM-COATED TABLETS
Each tablet of SOLIFENACIN-TRIMA 5 contains:
Solifenacin succinate 5 mg
Each tablet of SOLIFENACIN-TRIMA 10 contains:
Solifenacin succinate 10 mg
Inactive ingredients and allergens: see section 2 under ’Important
information about some ingredients of the medicine’ and section 6
‘Additional
information’.
READ THE ENTIRE LEAFLET CAREFULLY BEFORE USING THE MEDICINE. This
leaflet contains concise information about the medicine. If you have
any other questions, refer to the doctor or the pharmacist.
This medicine has been prescribed for you. Do not pass it on to
others. It may harm them, even if it seems to you that their medical
condition is similar.
DO NOT USE IN CHILDREN AND ADOLESCENTS UNDER THE AGE OF 18.
1. WHAT IS THE MEDICINE INTENDED FOR?
This medicine is intended for the treatment of urinary incontinence
and/
or conditions of increased urinary frequency and urgency in patients
with overactive bladder.
THERAPEUTIC CLASS: anticholinergic . BEFORE USING THE MEDICINE
DO NOT USE THIS MEDICINE:
If you are sensitive (allergic) to the active ingredient or to any of
the additional ingredients the medicine contains.
In case of urinary retention, severe gastrointestinal disorders
(toxic megacolon), myasthenia gravis (severe muscle weakness),
or
intraocular
pressure
accompanied
by
decreased
vision
(glaucoma).
In kidney patients undergoing dialysis and in patients with
severe
liver
insufficiency.
In patients with severe kidney disease or moderate liver disease
who are being treated concomitantly with another medicine that
decreases the removal of SOLIFENACIN-TRIMA from the body such
as ketoconazole.
SPECIAL WARNINGS REGARDING THE USE OF THE MEDICINE:
BEFORE STARTING TREATMENT WITH SOLIFENACIN-TRIMA, INFORM YOUR
DOCTOR IF:
You have a problem passing urine (partial obstruction), you suffer
from constipatio